Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Neglected Tropical Diseases Diagnosis
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.4 Billion by the ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of ... Read More
-
Huntington`s Disease Therapeutics
... at a CAGR of 31.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 40.0% CAGR The Huntington`s Disease Therapeutics market in the U.S. ... Read More
-
Inflammatory Bowel Disease (IBD) Therapeutics
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. TNF Inhibitor Drugs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 ... Read More
-
Narcolepsy Therapeutics
... CAGR of 7.1% over the analysis period 2024-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Apoptosis
... 4.6% over the analysis period 2024-2030. Apoptosis Assay Kits, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$3.9 Billion by the end of the analysis period. ... Read More
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Tinea Pedis (Athlete`s Foot) Treatment
... Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Topical Treatment, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$756.3 Million ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Duchenne Muscular Dystrophy Drugs
... 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Exon Skipping Therapy, one of the segments analyzed in the report, is expected to record a 42.6% CAGR and reach US$19.7 Billion by ... Read More
-
Pathology Instruments
... CAGR of 5.6% over the analysis period 2024-2030. Molecular Diagnostics Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the ... Read More
-
Gastrointestinal Therapeutics
... CAGR of 5.1% over the analysis period 2024-2030. Crohn`s Disease End-Use, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Myasthenia Gravis Drugs
... at a CAGR of 6.6% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Organs-on-Chips
... 35.3% over the analysis period 2024-2030. Liver-on-a- Chip, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth ... Read More
-
Post-Traumatic Stress Disorder (PTSD) Therapeutics
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by ... Read More
-
Single-Use Bioprocessing
... CAGR of 20.8% over the analysis period 2024-2030. Single-Use Media Bags & Containers, one of the segments analyzed in the report, is expected to record a 22.6% CAGR and reach US$29.9 Billion by the end ... Read More
-
Pruritus Therapeutics
... CAGR of 4.6% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
Research Assistance
